文献速递免疫规划传染病防控与疫情报告

乌干达HIV感染成人对乙型肝炎疫苗的免疫应答

Immune response to the hepatitis B vaccine among HIV-infected adults in Uganda.
PubMed 文献 · Vaccine · 2021-01-28

在乌干达坎帕拉纳入无既往HBV感染血清学证据的HIV感染成人,按0、1、6月接种三剂HBV疫苗,第三剂后4周测抗-HBs。251例筛查者中132例(53%)无既往HBV感染或免疫而入选,117例(92%)发生血清转换,109例(86%)为高水平应答;多因素分析仅基线CD4>200 cells/mm3与应答相关。

要点

  • HIV感染成人接种三剂HBV疫苗后92%血清转换、86%高水平应答。
  • 基线CD4>200 cells/mm3与应答及高水平应答独立相关。
  • 筛查的HIV感染者中约半数无HBV感染或免疫证据。

核心结论

  • HBV疫苗接种在HIV感染成人中能有效诱导体液保护性应答,尤其CD4计数较高者。
  • 乌干达HIV阳性成人中约半数筛查者无HBV免疫,提示存在较大HBV感染高危人群。
  • 研究结果支持将HBV疫苗纳入HIV阳性成人的常规照护。

研究设计与样本

  • 在乌干达坎帕拉纳入无既往HBV感染血清学证据的HIV感染成人。
  • 于0、1、6月接种三剂HBV疫苗,第三剂后4周检测抗-HBs水平。
  • 应答定义为抗-HBs≥10 IU/L,高水平应答定义为抗-HBs≥100 IU/L,采用回归分析确定应答预测因素。
  • 251例HIV阳性成人筛查,132例(53%)无既往HBV感染或免疫而入选。
  • 入选者中女性89例(67%),年龄中位数(IQR)32岁(27-41),68例(52%)接受ART>3个月,CD4中位数(IQR)426(261-583)cells/mm3。

主要发现

  • 117例(92%)参与者发生血清转换(抗-HBs≥10 IU/L)。
  • 109例(86%)参与者为高水平应答(抗-HBs≥100 IU/L)。
  • 多因素分析中仅基线CD4>200 cells/mm3与应答相关[OR=6.97(1.34-34.71),p=0.02]。
  • 基线CD4>200 cells/mm3与高水平应答相关[OR=4.25(1.15-15.69),p=0.03]。
  • 接受ART的68例中64例(94%)血浆HIV RNA检测不到。

关键数值与推荐

  • 应答判定:抗-HBs≥10 IU/L;高水平应答:抗-HBs≥100 IU/L。
  • 疫苗接种程序:0、1、6月各一剂,共三剂。
  • 免疫应答评估时间:第三剂后4周。

临床怎么用

  • 对HIV感染成人可按0、1、6月程序接种HBV疫苗以诱导保护性抗体。
  • 接种前可筛查HBV血清学,识别无免疫者并优先接种。
  • 基线CD4≤200 cells/mm3者应答较低,需关注接种后应答评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Co-infection with hepatitis B virus (HBV) and human immunodeficiency virus (HIV) is common in sub-Saharan Africa (SSA) and can rapidly progress to cirrhosis and hepatocellular carcinoma. Recent data demonstrate ongoing HBV transmission among HIV-infected adults in SSA, suggesting that complications of HIV/HBV co-infection could be prevented with HBV vaccination. Because HBV vaccine efficacy is poorly understood among HIV-infected persons in SSA, we sought to characterize the humoral response to the HBV vaccine in HIV-seropositive Ugandan adults. METHODS: We enrolled HIV-infected adults in Kampala, Uganda without serologic evidence of prior HBV infection. Three HBV vaccine doses were administered at 0, 1 and 6 months. Anti-HBs levels were measured 4 weeks after the third vaccine dose. "Response" to vaccination was defined as anti-HBs levels ≥ 10 IU/L and "high response" as ≥ 100 IU/L. Regression analysis was used to determine predictors of response. RESULTS: Of 251 HIV-positive adults screened, 132 (53%) had no prior HBV infection or immunity and were enrolled. Most participants were women [89 (67%)]; median (IQR) age was 32 years (27-41), and 68 (52%) had received antiretroviral therapy (ART) for > 3 months. Median (IQR) CD4 count was 426 (261-583), and 64 (94%) of the 68 receiving ART had undetectable plasma HIV RNA. Overall, 117 (92%) participants seroconverted to the vaccine (anti-HBs ≥ 10 IU/L), with 109 (86%) participants having high-level response (anti-HBs ≥ 100 IU/L). In multivariate analysis, only baseline CD4 > 200 cells/mm3 was associated with response [OR = 6.97 (1.34-34.71), p = 0.02] and high-level response [OR = 4.25 (1.15-15.69)], p = 0.03]. CONCLUSION: HBV vaccination was effective in eliciting a protective humoral response, particularly among those with higher CD4 counts. Half of the screened patients did not have immunity to HBV infection, suggesting a large at-risk population for HBV infection among HIV-positive adults in Uganda. Our findings support including HBV vaccination as part of routine care among HIV-positive adults.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Seremba E, Ocama P, Ssekitoleko R, et al. Immune response to the hepatitis B vaccine among HIV-infected adults in Uganda. Vaccine. 2021. PMID: 33516601. doi:10.1016/j.vaccine.2021.01.043

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。